ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Pharmacology & Therapeutics
Volume 108, Issue 1, October 2005, Pages 94-108
Discovery, Development and Implementation of Novel Pharmacotherapies for Addiction
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (214 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.pharmthera.2005.06.010    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2005 Elsevier Inc. All rights reserved.

Associate editor: T.C. Napier

Medications development: Successes and challenges

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Frank Voccia, Corresponding Author Contact Information, E-mail The Corresponding Author and Walter Lingb

aDivision of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Ste 4123, MSC 9551, Bethesda, MD 20892, United States

bIntegrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, United States


Available online 3 August 2005.

Abstract

The National Institute on Drug Abuse has funded a medications program that has concentrated on the development of medications for opiate and cocaine dependence. Levomethadyl acetate (LAAM) and buprenorphine and buprenorphine/naloxone sublingual tablets were developed in conjunction with pharmaceutical partners and approved by the Food and Drug Administration. The remaining challenges for medications development for opiate dependence involves Phase IV studies in special populations, for example, pregnant opiate-dependent patients, and to translate neuroscience-based findings into treatments. Several marketed medications have shown initial efficacy to reduce cocaine use in well-controlled clinical trials. Disulfiram has been shown to reduce cocaine use in several clinical trials, while baclofen, modafinil, naltrexone, ondansetron, tiagabine, and topiramate have shown preliminary efficacy in initial clinical studies. Confirmatory studies of many of these medications is underway. More recently, the NIDA medications program has evaluated medications for their ability to reduce methamphetamine use. To date, no medications tested have shown efficacy to reduce methamphetamine use. Both marketed medications and investigational agents will be tested. Finally, NIDA has begun to test medications for efficacy to reduce cannabis use. Initial studies are underway. Both agonist and antagonist approaches will be evaluated. Additionally, medications will be tested in cannabis-dependent patients for the management of insomnia, withdrawal, and concurrent depression.

Keywords: Medications; Opiate; Cocaine; Methamphetamine; Marijuana; Cannabis

Article Outline

1. Introduction
2. Opiate dependence
3. Medications for opiate dependence: successes
4. Future challenges for opiate dependence
5. Cocaine dependence
6. Medications for cocaine dependence: successes
6.1. Baclofen
6.2. Tiagabine
6.3. Topiramate
6.4. Naltrexone
6.5. Modafinil
7. Medications for cocaine dependence: challenges
8. Methamphetamine dependence
9. Marijuana dependence
References

Corresponding Author Contact InformationCorresponding author. Tel.: 301 443 6173; fax: 301 443 2599.

Pharmacology & Therapeutics
Volume 108, Issue 1, October 2005, Pages 94-108
Discovery, Development and Implementation of Novel Pharmacotherapies for Addiction
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.